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Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor superfamily, has been shown to have
inhibitory effect on many tumor types. However, the effect of BMP-2 on human renal cell carcinoma (RCC) is still unknown. We
previously showed that BMP-2 inhibits tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cells. Our study
investigates the effect of BMP-2 on human RCC using ACHN and Caki-2 cell lines. Three types of BMP receptors were found to
be expressed in ACHN and Caki-2 cells. In vitro, BMP-2 was found to inhibit the growth of ACHN and Caki-2 cells. The
antiproliferative effect seems to be due to cell cycle arrest in the G1 phase, which was revealed by flow cytometry analysis.
Using reverse transcriptase polymerase chain reaction analysis, we demonstrated BMP-2 upregulated osteogenic markers
Runx-2 and Collagen Type I gene expression in ACHN and Caki-2 cells. Treatment of ACHN and Caki-2 cells with BMP-2
induced a rapid phosphorylation of Smad1/5/8. In vivo, all animals receiving low number of ACHN (1 3 104) and Caki-2 (5 3
104) cells treated with 30 lg of BMP-2 per animal showed limited tumor growth with significant bone formation, whereas
untreated cells developed large tumor masses without bone formation in immunodeficient non-obese diabetic (NOD)/severe
combined immunodeficient (SCID) mice. These results suggest that BMP-2 inhibits growth of RCC as well as causes induction
of osseous bone formation. Further research is needed to determine the relationship between inhibition of cell proliferation
and bone induction.
Renal cell carcinoma (RCC) is the eighth most common can-
cer and highly lethal, accounting for about 13,120 deaths in
the United States in 2011.1 The incidence continues to
increase by 2% worldwide yearly. The major cause of death
from RCC is metastasis that is resistant to therapy.2 RCC
most commonly metastasizes to lung, bone, liver and brain.
Approximately 35% of patients with metastases have skeletal
complications causing pathological fractures, nerve compres-
sion syndromes, severe pain and hypercalcemia.3 Although
radiation therapy is often used as adjuvant treatment for
bone lesions, it is often ineffective in slowing disease progres-
sion in the skeleton or indeﬁnitely relieving pain. Bone me-
tastases in RCC mainly cause destructive osteolytic lesions in
bone and lead to marked morbidity.4 Therefore, to more
effectively control this disease and to improve patient survival
rate, there is an urgent need to develop new treatment
options for preventing RCC tumor cell growth.
Bone morphogenetic protein-2 (BMP-2) has the capability
to induce the entire cascade of cartilage and bone formation
in vivo.5 Besides inducing bone formation, BMP-2 has also
been shown to play important roles in the regulation of vari-
ous cellular processes, including cell differentiation, prolifera-
tion, morphogenesis, cellular survival and apoptosis.6,7 Simi-
lar to transforming growth factor (TGF)-b, BMP-2 exerts its
effect via speciﬁc Type 1 and Type 2 transmembrane serine/
threonine kinase receptors (BMPR). Binding of BMP-2 to the
Type 2 receptor induces oligomerization of the receptor com-
plex, leading to phosphorylation of the Type 1 receptor and
recruitment of downstream signaling Sma- and Mad-related
proteins (Smads). As a result, Smad1, Smad5 and Smad8 are
activated by BMP-2 receptors. Phosphorylated Smad1/5/8
forms a complex with Smad4 and then translocates to the
nucleus to modulate the transcription of a variety of target
genes that mediate the biological activity of BMP-2.8,9
More recently, BMP-2 has been demonstrated to play dif-
ferent roles on cancer cells dependent on the tissue type and
environment. BMP-2 has been shown to stimulate the growth
of pancreatic carcinoma, lung carcinoma and prostate cancer
cells in the absence of androgen.10–12 On the other hand,
BMP-2 clearly inhibits the growth of tumor cells of many
origins including breast cancer,13,14 myeloma,15 gastric can-
cer,16 colon cancer17 and prostate cancer.12,18 Our previous
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study also showed that BMP-2 inhibits the tumorigenicity of
cancer stem cells in the human osteosarcoma OS99-1 cells.19
To date, there are no published studies on the impact of
recombinant human BMP-2 (rhBMP-2) on human RCC.
rhBMP-2 is currently approved by the United States Food
and Drug Administration to promote certain spinal fusions
and is commercially available for clinical application for bone
repair. We hypothesized that rhBMP-2 might be used for
RCC bone metastasis to facilitate bone growth after surgical
resection if rhBMP-2 could exert an inhibitory effect on the
growth of human RCC.
Material and Methods
Cell culture
Human renal carcinoma cell lines ACHN and Caki-2 were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA). Cells were cultured in Dulbecco’s
modiﬁed Eagle medium/F12 medium (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (Gibco) in
a humidiﬁed atmosphere of 5% CO2 in air at 37C.
Cell proliferation assay
To investigate the effects of BMP-2 on cell growth, ACHN
and Caki-2 cells were inoculated at 5  103 cells per well in
96-well culture plates. The following day, the culture medium
was changed to 1% serum-containing medium, and the cells
were grown for 24 hr. Cells were then treated with 10, 100 or
300 ng/ml of rhBMP-2 (GenScript Corporation, Piscataway,
NJ) or vehicle control for 24, 48 and 72 hr. Cell growth was
evaluated using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay (Promega, Madison, WI) as described previously.19
Cell cycle analysis
For cell cycle analysis by ﬂow cytometry, ACHN and Caki-2
cells were inoculated in six-well culture plates. The following
day, the culture medium was changed to 1% serum-contain-
ing medium, and the cells were grown for 24 hr. Cells treated
with 300 ng/ml of BMP-2 or vehicle control for 48 hr were
then ﬁxed with 70% ethanol for 20 min on ice. Cells were
suspended in PBS containing 50 lg/ml of propidium iodide
(Invitrogen, Grand Island, NY) and 100 lg/ml of RNase
(Invitrogen) to stain nuclear DNA for 30 min at room tem-
perature. DNA content was analyzed using ﬂow cytometry
(Becton Dickinson, San Jose, CA). Data were analyzed for
DNA histograms using BD CellQuest software (Becton
Dickinson).
Flow-cytometric analysis of apoptosis
To determine whether BMP-2 could induce apoptosis, ACHN
and Caki-2 cells were inoculated in six-well culture plates. The
following day, the culture medium was changed to 1% serum-
containing medium, and the cells were grown for 24 hr. Cells
were then treated with 300 ng/ml of BMP-2 or vehicle control
for 48 hr. Annexin V-cy3-labeled Apoptosis Detection Kit
(Invitrogen) was used for the detection of apoptotic cells by
ﬂow cytometry as described previously.20 Data were analyzed
using CellQuest software (Becton Dickinson).
Semiquantitative reverse transcriptase polymerase chain
reaction
To test the expression of BMP receptors in ACHN and Caki-
2 cells, semiquantitative polymerase chain reaction (PCR)
was performed as described previously.19 The PCR primers
included BMPR1A (forward, 50-AAT GGAGTAACCTTAG-
CACCAGAG-30; reverse, 50-AGCTGAGTCCAGGAACCTG-
TAC-30), BMPR1B (forward, 50-GGTTGCCTGTGGTCACTT
CTGG-30; reverse, 50-TAGTCTGTG ATTAGGTACAACTG
G-30), BMPR2 (forward, 50-TCAGATATATGGCACCAGAA
GTG-30; reverse, 50-GTGGAGAGGCTGGTGACACTTG-30)
and b-actin (forward, 50-GCGGGAAAT CGTGCGTGACA
TT-30; reverse, 50-GGCAGATGGTCGTTTGGCTGAATA-30).
MCF-7 cell line was used as positive controls as described
previously.21
Quantitative real-time polymerase chain reaction
ACHN and Caki-2 cells were inoculated in 10-cm culture
dishes. The following day, the culture medium was changed
to 1% serum-containing medium, and the cells were grown
for 24 hr. Cells were then treated with 300 ng/ml of BMP-2
or vehicle control for the time indicated. Quantitative
real-time PCR (qRT-PCR) of osteogenic markers Runx-2
(Hs00231692_m1) and Collagen Type I (Hs00164004_m1),
BMPR1A (Hs01034913_g1), BMPR1B (Hs00176144-m1),
BMPR2 (Hs00176148-m1) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene expression were conducted
using Eppendorf Mastercycler Realplex Detection System
(Eppendorf, Germany), as we previously described.19 Real-
time quantitative primers were designed and purchased from
Applied Biosystems. A positive standard curve for each
primer was obtained using serially diluted cDNA sample
mixture. The quantity of gene expression was calculated
using standard samples and normalized with GAPDH.
Immunocytochemical staining
Immunocytochemistry was performed using three antibodies:
BMPR1A, BMPR1B and BMPR2 (1:50; Santa Cruz Biotech-
nology, Santa Cruz, CA). Immunoﬂuorescent staining was
performed as we previously reported.22,23 Digital images were
captured using an Olympus microscope (Olympus America,
Milville, NY).
Western blot analysis
Cells treated with BMP-2 (300 ng/ml) or vehicle control were
lysed using radioimmunoprecipitation assay (RIPA) buffer
(Thermo Scientiﬁc, Pittsburgh, PA) supplemented with prote-
ase inhibitor (Promega), phenylmethanesulfonyl ﬂuoride
(Sigma, Brooklyn, NY) and PhosStop (Roche, Basel, Switzer-
land). The protein concentrations were then measured using
bicinchoninic acid (BCA) assay (Thermo Scientiﬁc). Next, the
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protein lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then transferred onto
hybond-C pure nitrocellulose membrane (Amersham, Piscat-
away, NJ). Membranes were blocked with Tris-buffered saline
(TBS) containing 0.1% Tween 20 with 5% nonfat dry milk,
and then incubated with antiphospho-Smad1/5/8 or anti-
GAPDH (Cell Signaling Technology, Danvers, MA) over-
night. After washing with TBS with Tween 20, the secondary
antibodies were added. Finally, the proteins were visualized
with the enhanced chemiluminescence (ECL) chemilumines-
cence system (Amersham).
In vivo cotreatment experiments
Our previous results indicated that 30 lg of BMP-2 could in-
hibit the tumorigenicity of cancer stem cells in human osteo-
sarcoma OS99-1 cells in immunodeﬁcient non-obese diabetic
(NOD)/severe combined immunodeﬁcient (SCID) (NOD/
SCID) mice19; therefore, 30 lg of BMP-2 was used to exam-
ine the tumor inhibitory effect of BMP-2 on ACHN and
Caki-2 cells. BMP-2 (30 lg) was coated with Afﬁ-Gel blue
beads (Bio-Rad Laboratories, Philadelphia, PA) at 37C for 1
hr as described previously.24 Different numbers of ACHN
and Caki-2 cells were suspended in 100 ll of Afﬁ-Gel blue
beads, cells treated with the same volume of vehicle were
used as a control and then cells with BMP-2 or vehicle con-
trol mixed with Matrigel (1:1 volume; BD Biosciences, San
Jose, CA) were subcutaneously injected into right and left
lower abdominal area of NOD/SCID mice (Harlan Laborato-
ries, Indianapolis, IN). Tumor growth was monitored weekly
for 12 weeks. Tumors formed were removed, and a portion
of each tumor was processed for histological analysis. All ani-
mal studies were performed according to protocol approved
by the Institutional Animal Care and Use Committee of the
University of Michigan.
In vivo assessment of bone formation
After the mice were killed, radiographs were obtained using
the Faxitron X-ray (Faxitron X-ray Corp., Lincolnshire, IL).
For microcomputed tomography (micro-CT) analysis, speci-
mens were scanned on a micro-CT scanner (EVS Corpora-
tion, Memphis, TN). GEMS MicroView software (GE Health-
care Biosciences, Piscataway, NJ) was used to make a three-
dimensional reconstruction from the set of scans. For histo-
morphometry, specimens were stained for hematoxylin and
eosin (H&E) staining and Masson’s trichrome staining to
show Collagen Type I protein in the newly formed bone.
Undecalciﬁed sections were stained with von-Kossa staining
to identify the calciﬁcation during osteogenesis in the tumor.
Statistical analysis
Data were expressed as the mean 6 standard deviation. Stat-
istically signiﬁcant differences were determined using SPSS
11 software (SPSS, Chicago, IL). A p-value of <0.05 was con-
sidered statistically signiﬁcant.
Results
Expression of BMP receptors in ACHN and Caki-2 cells
BMP-2 induces a physiological response through the activa-
tion of receptors speciﬁc for the BMP-2. Intracellular activa-
tion begins with BMP-2 binding to Type 2 receptor, which
leads to the binding of this complex to either Type 1A or 1B
receptor and then phosphorylates the Smad transcription fac-
tors.9 To determine whether the BMP-2 receptors are
expressed in ACHN and Caki-2 cells, we ﬁrst sought to
investigate the mRNA expression of BMPR1A, BMPR1B and
BMPR2. PCR analysis revealed that BMPR1A, BMPR1B and
BMPR2 were expressed in ACHN and Caki-2 cells as shown
in Figure 1a, and real-time PCR demonstrated that BMP
receptors are more expressed in Caki-2 cells than in ACHN
cells (Fig. 1b). All three types of BMP receptors were further
demonstrated to be present in ACHN (Figs. 1c–1e) and Caki-
2 (Figs. 1f–1h) cells by immunoﬂuorescent staining. These
data suggest that human RCC cells have the potential capa-
bility of being activated by the BMP-2 ligand.
BMP-2 inhibits the proliferation of ACHN and Caki-2 cells
The proliferation activity of ACHN and Caki-2 cells was
examined by MTS assay after BMP-2 (0, 10, 100 or 300 ng/
ml) treatment for 24, 48 and 72 hr. As shown in Figure 2,
the proliferation of cells treated with 300 ng/ml of BMP-2
was signiﬁcantly inhibited at 24 hr and tended to be more
signiﬁcant at 48 and 72 hr. Treatment of cells with 10 ng/ml
at the three time points induced a stimulation of cell growth
to a lesser but signiﬁcant extent, whereas ACHN and Caki-2
cells demonstrated modest but signiﬁcant decreases in growth
when treated with 100 ng/ml of BMP-2 at the three time
points (Figs. 2a and 2b). As 300 ng/ml of BMP-2 signiﬁcantly
produced an inhibitory effect in cell growth in ACHN and
Caki-2 cells, we chose this dose for the following experiments
in vitro.
BMP-2 induces G1 cell cycle arrest but has no effect on
apoptosis in ACHN and Caki-2 cells
A possible explanation for the observed growth inhibition of
ACHN and Caki-2 cells in response to BMP-2 is either apo-
ptosis or inhibition of new DNA synthesis. We next exam-
ined the effects of BMP-2 on ACHN and Caki-2 cell cycle
progression and apoptosis by ﬂow cytometry. ACHN (Fig.
3a) and Caki-2 (Fig. 3b) cells incubated with 300 ng/ml of
BMP-2 for 48 hr showed approximately 30 and 37%
decreases in the S-phase, respectively, compared to controls.
The decrease in the S-phase population was accompanied by
an increase in the cell number at the G1 phase of the cell
cycle. ACHN and Caki-2 cells incubated with 300 ng/ml of
BMP-2 for 48 hr showed approximately 15 and 7% increases
in the G1 phase, respectively, compared to controls. Because
apoptosis may be one of the consequences of cell cycle arrest,
we then examined whether BMP-2 induces apoptosis in
ACHN and Caki-2 cells using Annexin V staining, which
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detects early apoptosis by binding to membrane phospholipid
translocated from the inner to the outer leaﬂet of the plasma
membrane during apoptosis.25 Our results indicated that no
cell apoptosis was shown by annexin V staining at 48 hr after
treatment in ACHN and Caki-2 cells (Fig. 3c). These data
suggest that BMP-2 inhibits ACHN and Caki-2 cell prolifera-
tion by arresting them at the G1 phase of the cell cycle.
BMP-2 upregulates expression of osteogenic markers in
ACHN and Caki-2 cells
BMP-2 has been shown to upregulate osteogenic marker in
human prostate cancer cells and osteosarcoma cells.18,19 We
therefore sought to determine whether BMP-2 upregulates
the transcription of osteogenic markers Runx-2 and Collagen
Type I in human RCC cells. ACHN and Caki-2 cells treated
with BMP-2 at 300 ng/ml were assayed for Runx-2 and Col-
lagen Type I mRNA level by qRT-PCR. Cells treated with the
same volume of vehicle were used as a control. As shown in
Figure 4a, the increased Runx-2 in ACHN cells was signiﬁ-
cantly detected as early as the ﬁrst 30 min of stimulation and
sustained for 8 hr of BMP-2 stimulation and then showed
increased trend until 48 hr after BMP-2 treatment, whereas
Collagen Type I in ACHN cells exhibited a continuous
increase as early as the ﬁrst 30 min of stimulation and had a
Figure 1. Expression of BMP receptors in ACHN and Caki-2 cells. (a) Messenger RNA transcripts for BMP receptors. Lane 1: negative
control; Lane 2: ACHN cells; Lane 3: Caki-2 cells; Lane 4: MCF-7 cells (positive control). (b) Relative quantitative mRNA expression of
BMPR1A, BMPR1B and BMPR2 genes in ACHN and Caki-2 cells. Gene expression levels were normalized to b-actin. BMP receptors are more
expressed in Caki-2 cells than in ACHN cells (*p < 0.05). Representative immunofluorescent staining of BMPR1A, BMPR1B and BMPR2 in
ACHN (c–e) and Caki-2 (f–h) cells. The nuclei counterstained with 40,6-diamidino-2 phenylindole (DAPI; blue areas). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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signiﬁcant increase at 1 hr of BMP-2 stimulation and had an
approximately 15-fold increase at 48 hr after BMP-2 treat-
ment (Fig. 4b). Figure 4c shows that Runx-2 in Caki-2 cells
continuously increased starting 30 min and had a signiﬁcant
increase at 1 hr of BMP-2 stimulation and sustained the
increase 48 hr after BMP-2 treatment, whereas the increased
Collagen Type I in Caki-2 cells was signiﬁcantly detected as
early as 2 hr and had an approximately threefold increase 48
hr after BMP-2 treatment (Fig. 4d). These data revealed that
osteogenic markers Runx-2 and Collagen Type I were upregu-
lated by BMP-2 in ACHN and Caki-2 cells.
BMP-2 activates Smad1/5/8 in ACHN and Caki-2 cells
To determine whether BMP-2 signaling pathways were func-
tional in these two cell lines, we stimulated cells with BMP-2
and examined the phosphorylation and nuclear translocation
of Smad1/5/8, because BMP-2 is thought to predominantly
act through the activation of these transcription factors.26
The ability of BMP-2 to phosphorylate Smad1/5/8 was ﬁrst
detected by Western blot analysis using an antibody that spe-
ciﬁcally recognizes the phosphorylated forms after cells were
treated with BMP-2 or vehicle control. As shown in Figure
5a, phosphorylation of Smad1/5/8 in ACHN and Caki-2 cells
was induced as early as 5 min of treatment with 300 ng/ml
of BMP-2 and remained elevated after 48 hr of treatment.
Localization of phosphorylated Smad1/5/8 was also examined
by immunoﬂuorescent staining in cultured ACHN and Caki-
2 cells. Consistent with the results obtained by Western blot
analysis, phosphorylated Smad1/5/8 was clearly shown in the
nuclei of ACHN and Caki-2 cells treated with BMP-2 at 300
ng/ml for 30, 60 and 90 min, respectively (Fig. 5b). These
results revealed that BMP receptors are functional and BMP-
2 can induce a classical Smad signaling pathway in ACHN
and Caki-2 cells.
BMP-2 induces bone formation in ACHN and Caki-2
cells in vivo
On the basis of the previous ﬁndings, we reasoned that if
BMP-2 induces osteogenic marker expression, it might
induce bone formation in vivo. Therefore, we next injected
ACHN and Caki-2 cells with BMP-2 or vehicle control sub-
cutaneously into NOD/SCID mice. Injection of 30 lg of
BMP-2 per animal was chosen based on our prior work on
human osteosarcoma cells, in which BMP-2 inhibits the
tumorigenicity of cancer stem cells in human osteosarcoma
OS99-1 cell line in vivo.19 Experiments were performed as
previously described.27 At 12 weeks after BMP-2 treatment,
the animals were euthanized and the bone formations were
evaluated. No bone formation was found in eight mice with
injection of 1  106 ACHN and Caki-2 cells with BMP-2
treatment, and conversely, the cells treated with 30 lg
BMP-2 per animal generated bigger tumors in NOD/SCID
mice than cells without BMP-2 counterpart (data not
shown). When as many as 1  105 ACHN and Caki-2 cells
with BMP-2 treatment were injected, no bone formations
but smaller tumors were observed in eight mice. All four
animals receiving 1  104 ACHN cells treated with 30 lg of
BMP-2 per animal exhibited retarded tumor growth with
signiﬁcant bone formation, whereas untreated cells exhibited
tumor growth without bone formation in NOD/SCID mice
(Figs. 6a and 6b). For Caki-2 cells, bone formations were
found in all four mice with the injection of 5  104 cells
with BMP-2 treatment. The resulting bone ossicles were
evaluated by radiograph and micro-CT. The dense bony
ossicles were clearly visualized by radiograph and micro-CT
in the ACHN and Caki-2 cells with BMP-2 treatment (Fig.
6c), whereas no bony ossicles were found in the cells with-
out BMP-2 counterpart (data not shown). Subsequent histo-
pathological analyses with H&E, Masson’s trichrome and
Von Kossa staining conﬁrmed that bone formation induced
by ACHN and Caki-2 cells with BMP-2 treatment. As
shown in Figure 6d, the sections with Masson’s trichrome
staining showed blue collagen in the newly formed bone,
whereas the sections stained with von-Kossa staining clearly
showed calciﬁed bone matrix. These results suggest that
Figure 2. BMP-2 inhibits the proliferation of ACHN and Caki-2
cells. ACHN and Caki-2 cells were inoculated in 96-well plates at 5
 103 cells per well. The following day, the culture medium was
changed to 1% serum-containing medium, and then the cells were
grown for 24 hr. Cells were treated with 10, 100 or 300 ng/ml of
BMP-2 or vehicle control for 24, 48 and 72 hr. Growth of ACHN
cells (a) and Caki-2 cells (b) was significantly inhibited by the
addition of 300 ng/ml of BMP-2 for 24, 48 and 72 hr (*p < 0.05;
**p < 0.001). The results are representative of six independent
experiments. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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BMP-2 inhibited tumor growth by inducing bone formation
in ACHN and Caki-2 cells in vivo.
Discussion
RCC is the most common malignant tumor arising from the
kidney and it accounts for more than 30,000 new cases yearly
in the United States.28 Surgical resection of the primary
tumor is the mainstay of treatment. However, 25–30% of
patients present with metastatic disease at the time of diagno-
sis.29 Metastatic RCC is a highly fatal disease. The tumor is
chemoresistant to currently available therapies. The meta-
static bone lesions are destructive and relatively resistant to
local treatment with radiation. Pathological fractures of bone
containing metastases are frequently treated by surgeons
because metastatic bone tumors are more common than pri-
mary malignant bone tumors.30
Figure 3. BMP-2 induces G1 cell cycle arrest but has no effect on apoptosis in ACHN and Caki-2 cells. ACHN and Caki-2 cells treated with
300 ng/ml of BMP-2 or vehicle control for 48 hr were analyzed for cell cycle by flow cytometry. ACHN (a) and Caki-2 (b) cells exhibited
approximately 30 and 37% decreases in the S-phase, respectively, compared to controls. (c) ACHN and Caki-2 cells treated with 300 ng/ml
of BMP-2 or vehicle control for 48 hr were stained with FITC-conjugated Annexin V in a buffer containing propidium iodide (PI) and
analyzed by flow cytometry. The lower right quadrant indicates the percentage of early apoptotic cells. No more apoptotic cells were found
in ACHN and Caki-2 cells with BMP-2 treatment than those without BMP-2 treatment. The results are representative of three independent
experiments. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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BMP-2, a member of the TGF-b superfamily, was origi-
nally investigated for its ability to induce the entire cascade
of cartilage and bone formation in vivo.5 More recently,
BMP-2 has been shown to produce a complex set of effects
in cancers. BMP-2 appears to have an inhibitory effect on
many tumors including breast cancer, myeloma, gastric can-
cer, colon cancer and prostate cancer.12–18 Treatment of
human osteosarcoma-derived tumor-initiating cells with
BMP-2 has also been observed to inhibit cell proliferation,
induction of differentiation and importantly reduce the abil-
ity to form tumors in immunodeﬁcient mice.19 Conversely,
BMP-2 has also been found to stimulate the growth of pan-
creatic carcinomas, lung carcinoma and prostate cancer.10–12
However, no evidence on the effect of BMP-2 on human
RCC cells has been reported.
In our study, we sought to examine the effect of BMP-2 on
human RCC using human RCC ACHN and Caki-2 cell lines.
It has been reported that BMP signaling for the growth and
differentiation of normal or neoplastic cells is dependent on its
receptors.31 There are currently three characterized BMP
receptors: BMPR1A, BMPR1B and BMPRR2. Activation of the
BMP receptor complex initiates intracellular signaling trans-
duction.9 Using regular PCR and immunostaining, we demon-
strated that all three types of BMP receptors were expressed in
ACHN and Caki-2 cells, suggesting that BMP-2 could bind to
its receptors and activate cell signaling to affect RCC cell activ-
ities. Furthermore, we observed that BMP-2 had a signiﬁcant
inhibitory effect on ACHN and Caki-2 cell proliferation at a
concentration of 300 ng/ml compared to much lower concen-
trations. This result is consistent with previous studies that
have shown an inhibitory effect of BMP-2 on cancer cell
growth including prostate cancer, breast cancer, myeloma, gas-
tric cancer, colon cancer and osteosarcoma.12–18 A possible ex-
planation for the growth inhibition of ACHN and Caki-2 cells
in response to BMP-2 is either apoptosis or inhibition of new
DNA synthesis. Our results indicated that BMP-2 did not
induce subsequent cell apoptosis, but instead induced cell cycle
arrest in the G1 phase, consistent with results reported for gas-
tric cancer cell lines and prostate cancer cell lines.16,18
It has been reported that BMP-2 induces the differentia-
tion of uncommitted cells along with osteoblastic pathways
in several cell types including mesenchymal stem cells,
Figure 4. BMP-2 upregulates expression of osteogenic markers in ACHN and Caki-2 cells. Relative quantitative mRNA expression of Runx-2
and Collagen Type I genes in ACHN and Caki-2 cells treated with 300 ng/ml of BMP-2 for the time indicated. Gene expression levels were
normalized to GAPDH. Runx-2 in ACHN and Caki-2 cells was significantly detected as early as 30 min and 1 hr after BMP-2 treatment,
respectively (a and c), whereas Collagen Type I had a significant increase in ACHN and Caki-2 cells as early as 1 and 2 hr of BMP-2
treatment, respectively (b and d; *p < 0.05; **p < 0.001). Each experiment was performed three times; representative examples are shown.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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myoblast cells and malignant ﬁbrous histiocytoma cells.32–34
Runx-2 is a transcriptional factor known to regulate the
expression of bone-related factors in osteoblasts and thus
induce osteoblastic differentiation.35 Collagen Type I presents
by far the most predominant collagen in vertebrate organisms
and composes 85–90% of the total bone matrix.36 Runx-2
and Collagen Type I are known to be upregulated by BMP-2
in human prostate cancer cells and osteosarcoma cells.18,19
Therefore, using qRT-PCR, we found that Runx-2 was signiﬁ-
cantly upregulated in ACHN and Caki-2 cells treated with
BMP-2 at a concentration of 300 ng/ml as early as 30 min
and 1 hr after BMP-2 stimulation, respectively, compared
to untreated controls. Collagen Type I was signiﬁcantly
enhanced in ACHN and Caki-2 cells as early as 1 and 2 hr
after BMP-2 stimulation, respectively. These genes and their
transcripts are functional differentiation markers of osteoblas-
tic phenotype.37 Thus, our ﬁndings suggest that BMP-2 might
induce human RCC cells to express an osteoblastic phenotype
and thus activate osteogenic differentiation to form bone.
BMP-2 is thought to predominantly exert their effect via
binding to two types of receptors, leading to downstream trans-
duction of the BMP signal through phosphorylation of speciﬁc
intracellular proteins called Smads.8 To further explore whether
or not BMP-2 signaling pathways were functional in these two
cell lines, the phosphorylation and nuclear translocation of
Smad1/5/8 were detected by Western blot analysis and immu-
nostaining using an antibody that speciﬁcally recognizes the
phosphorylated Smad1/5/8. Our results indicated that phospho-
rylation of Smad1/5/8 in ACHN and Caki-2 cells was induced
as early as 5 min of treatment with 300 ng/ml of BMP-2 and
remained elevated after 48 hr of treatment. The elevation of
Smad activation at the 5-min time point, before Runx-2 and
Collagen Type I were signiﬁcantly upregulated at 30 min and 1
hr, suggests that transcription regulation of bone-related osteo-
genic markers Runx-2 and Collagen Type I gene expression by
BMP-2 was mediated via the Smads transducer.
Because in vitro analysis does not always reﬂect exactly
the in vivo situation, mouse experiments approximating in
Figure 5. BMP-2 activates Smad1/5/8 in ACHN and Caki-2 cells. Phosphorylated Smad1/5/8 in ACHN and Caki-2 cells treated with 300
ng/ml of BMP-2 or vehicle control was detected either by Western blot analysis or by using immunofluorescent staining. Phosphorylation of
Smad1/5/8 in ACHN and Caki-2 cells was induced as early as 5 min and remained elevated after 48 hr of treatment (a). Phosphorylated
Smad1/5/8 was clearly shown in the nuclei of ACHN and Caki-2 cells treated with BMP-2 for 30, 60 and 90 min (b). Equally loaded protein
amounts were demonstrated by detection of GAPDH. Each experiment was performed three times; representative examples are shown.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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vivo conditions are essential to conﬁrm cell culture results
and to assess the potential use of BMP-2 clinically. In our
study, we found that all animals receiving low numbers of
ACHN (1  104) and Caki-2 (5  104) cells treated with
30 lg of BMP-2 per animal resulted in retarded tumor
growth with signiﬁcant bone formation, whereas untreated
cells developed large tumor masses without bone formation
in NOD/SCID mice. The bone formation was further con-
ﬁrmed by radiograph and micro-CT and histopathological
analysis of sections from bony tissues formed by ACHN and
Caki-2 cells treated with BMP-2. Thus, exposure to BMP-2
induced bone formation with resultant limited tumor growth.
This result is consistent with previous studies of primary can-
cers that showed ossiﬁcation of tumor areas as a result of
BMP-2.38–40 In addition, Fong et al.41 reported that viral vec-
tor-induced expression of BMP-2 in a breast cancer cell line
and a colon cancer cell line induces calciﬁcation of tumors to
arrest tumor growth. However, we also found that large
number of ACHN and Caki-2 (1  106) cells treated with 30
lg of BMP-2 per animal induced a stimulation of tumor
growth, suggesting that the inhibitory effect of BMP-2 on tu-
mor growth may be related to tumor cell number. Therefore,
the effect of rhBMP-2 on cancer cell growth may depend not
only on the particular cell type, activity of BMP receptors
and growth environment but may also depend on the
rhBMP-2 dose used relative to the cancer cell density.
Although our report is the ﬁrst to provide data indicating
that BMP-2 has an inhibitory effect on human RCC ACHN
and Caki-2 cells by inducing bone formation, the use of two
cell lines provides limited evidence. Further research using
Figure 6. BMP-2 induces bone formation in ACHN and Caki-2 cells in vivo. (a and b) Representative tumor growth of ACHN cells without BMP-
2 treatment at the injection site in a NOD/SCID mouse. Smaller tumor formation was seen at the injection site with BMP-2 treatment
counterpart. (c) Representative bone formations generated from ACHN and Caki-2 cells with BMP-2 treatment were clearly demonstrated by
radiograph and micro-CT measurements of bony ossicles. Images are representative of n ¼ 4 animals per group. (d) Representative bone
nodule formations were further confirmed by H&E staining (left), Masson’s trichrome staining showing blue collagen (middle) and Von Kossa
staining showing calcified bone matrix (right). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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more cell lines and primary tumors is therefore necessary to
conﬁrm the ﬁndings of our study.
In conclusion, BMP-2 appears to cause cell cycle arrest in the
G1 phase of ACHN and Caki-2 cells. In addition, BMP-2 upregu-
lates osteogenic markers Runx-2 and Collagen Type I gene
expression in ACHN and Caki-2 cells, and this osteoinductive
effect may be mediated by Smad signaling pathway. Our ﬁndings
provide evidence on the potential therapeutic effectiveness of
BMP-2 on RCC. Further studies to delineate the relationship
between tumor growth inhibition and osteoinduction are needed.
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